In fact, Lai et al. identified Epirubicin as a drug that significantly induced RKIP levels when treating MCF-7 and MDA-MB-231 cells, two types of human breast cancer cell line, within a 24 hour period [207,210]. This evidence concerns the gene PEBP1 and breast cancer.